exhibition icon
register now icon
get brochure icon
sponsors icon
add event to diary icon
email this to... icon
contact us icon
Breakthrough
our speakers
Zhaosheng Lin
Head of Biomarkers
Pfizer
 
Nadine Cohen
Head of Pharmacogenomics
Johnson & Johnson
 
Mitchell B. Friedman
Director of Toxicology
Takeda Global R&D
 
Malcolm Mitchell
Medical Director, Clinical Pharmacology
Eli Lilly
 
Dr Russell Weiner
Group Director
Bristol-Myers Squibb
conference details
Conference:
Pre-conference workshop
19 Oct 9am - 5pm
Day 1
20 Oct 8.30am - 5:30pm
Day 2
21 Oct 8.30am - 5:30pm
Post-conference workshop
22 Oct 9am - 5pm
 
Venue: Boston, MA, United States

› Email a friend
› Add this to my calendar

Register online now 
or call +44 (0) 207 608 7055
Contact LIVE
Location
Exploratory Clinical Development World Americas 2010

Breakthrough

When: 20 Oct - 21 Oct
Where: Le Meridien Hotel, Cambridge Massachusetts
Category: Conference

Ms. Sasha Latypova, speaking at Exploratory Clinical Development World Americas 2010

Ms. Sasha Latypova,
Executive Vice President
iCardiac Technologies

Latypova is a co-founder of iCardiac Technologies, a venture-backed company from the University of Rochester Medical Center, engaged in the development of advanced ECG technologies and methods for cardiac safety assessment in drug development. Prior to iCardiac Technologies, Ms. Latypova headed business development at VirtualScopics, Inc., another University of Rochester spin-out and a leading developer of image-based biomarkers for pharmaceutical development. Prior to VirtualScopics, Ms. Latypova was a Manager in Healthcare practice at Analysis Group, Inc., a Boston-based health economics, financial and strategy consultancy, where she advised pharmaceutical clients on a wide range of issues concerning product development, and provided economic analyses for pharmaceutical litigation cases. Ms. Latypova holds Masters of Business Administration degree from the Amos Tuck School at Dartmouth College.
Appearing:
Day One, Wednesday 20 October 2010
3.30pm

“Right-Sized” Assessment of Cardiovascular Safety in Early Clinical Development

  • Common challenges of QT assessment
  • Potential strategies for incorporating QT assessment into early clinical studies
  • Case examples illustrating when QT assessment in early clinical studies is warranted and useful for future development programs
  • Examples of cost-effectiveness analysis to guide decision-making
Ms. Sasha Latypova,
Executive Vice President,
iCardiac Technologies
event sponsors

 

Follow us on Twitter
Twitter logo

› follow us! › tweet this!

Reserve a stand
Reserve an exhibition stand at the Exploratory Clinical Development World Americas exhibition - book early to ensure optimum stand placement!

 
Reserve a stand
 
For details contact
Claire Conway on +44 (0) 207 608 7058


comment / report a mistake | contact us | about Terrapinn | site map | privacy | T&Cs a terrapin ©Terrapinn Holdings Ltd. MMX